HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andreas du Bois Selected Research

Poly(ADP-ribose) Polymerase Inhibitors

11/2020Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
7/2020Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
6/2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
7/2010Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andreas du Bois Research Topics

Disease

100Ovarian Neoplasms (Ovarian Cancer)
02/2022 - 09/2003
72Neoplasms (Cancer)
04/2022 - 08/2004
33Ovarian Epithelial Carcinoma
05/2022 - 03/2006
26Breast Neoplasms (Breast Cancer)
05/2022 - 08/2004
20Carcinoma (Carcinomatosis)
04/2022 - 04/2005
8Neutropenia
01/2018 - 07/2011
7Residual Neoplasm
01/2022 - 12/2006
7Neoplasm Metastasis (Metastasis)
10/2021 - 01/2008
7Disease Progression
01/2020 - 01/2005
6Hypertension (High Blood Pressure)
11/2020 - 12/2011
5Ascites
01/2022 - 12/2006
5Diarrhea
01/2019 - 04/2007
4Fatigue
11/2020 - 10/2014
4Thrombocytopenia (Thrombopenia)
01/2018 - 10/2014
3Genomic Instability
02/2022 - 07/2010
3Anemia
11/2020 - 01/2016
3Alopecia (Baldness)
01/2020 - 05/2015
3Vulvar Neoplasms (Vulvar Cancer)
01/2020 - 03/2015
3Fallopian Tube Neoplasms
01/2016 - 04/2007
2Nausea
11/2020 - 01/2020
2Vomiting
11/2020 - 01/2020
2Sepsis (Septicemia)
01/2018 - 01/2016
2Sarcoma (Soft Tissue Sarcoma)
11/2016 - 03/2016
2Endometrial Neoplasms (Endometrial Cancer)
12/2015 - 09/2009
2Endometrioid Carcinoma
04/2014 - 01/2008
2Body Weight (Weight, Body)
12/2011 - 04/2009
2Pathologic Complete Response
09/2011 - 04/2010
2Lung Neoplasms (Lung Cancer)
07/2011 - 11/2010
2Adenocarcinoma
11/2010 - 01/2008
1Endometriosis
01/2022
1Turcot syndrome
01/2022
1Proteinuria
11/2020
1Hemorrhage
11/2020
1Pain (Aches)
10/2020
1Dyspnea (Shortness of Breath)
08/2020
1Hypesthesia (Numbness)
08/2020

Drug/Important Bio-Agent (IBA)

38PlatinumIBA
04/2022 - 04/2005
26Paclitaxel (Taxol)FDA LinkGeneric
02/2022 - 09/2003
24Carboplatin (JM8)FDA LinkGeneric
02/2022 - 09/2003
20taxaneIBA
04/2022 - 08/2004
13Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2009
10Pharmaceutical PreparationsIBA
01/2018 - 01/2005
10Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2013 - 08/2004
9AnthracyclinesIBA
11/2016 - 01/2005
8Epirubicin (Ellence)FDA LinkGeneric
07/2013 - 08/2004
7DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2008
7Hormones (Hormone)IBA
10/2021 - 04/2005
7Bevacizumab (Avastin)FDA Link
11/2020 - 12/2011
7liposomal doxorubicin (Doxil)FDA Link
01/2020 - 01/2010
7ErbB Receptors (EGF Receptor)IBA
01/2019 - 01/2005
7Trastuzumab (Herceptin)FDA Link
09/2011 - 04/2009
6GemcitabineFDA Link
01/2020 - 10/2006
6Docetaxel (Taxotere)FDA Link
11/2011 - 04/2005
5Biological ProductsIBA
01/2020 - 10/2010
5Doxorubicin (Adriamycin)FDA LinkGeneric
11/2016 - 04/2005
4Estrogen ReceptorsIBA
05/2022 - 06/2007
4Proteins (Proteins, Gene)FDA Link
04/2022 - 01/2009
4Poly(ADP-ribose) Polymerase InhibitorsIBA
11/2020 - 07/2010
4Messenger RNA (mRNA)IBA
01/2019 - 01/2016
4Topotecan (Hycamtin)FDA LinkGeneric
01/2018 - 08/2006
4pazopanibFDA Link
01/2018 - 10/2014
4human ERBB2 proteinIBA
09/2011 - 01/2009
4Capecitabine (Xeloda)FDA Link
04/2010 - 04/2009
4Cisplatin (Platino)FDA LinkGeneric
10/2006 - 09/2003
3nintedanibIBA
02/2022 - 01/2016
3Biological FactorsIBA
10/2021 - 03/2009
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
07/2020 - 07/2010
3pertuzumabIBA
01/2019 - 01/2016
3Transcription Factors (Transcription Factor)IBA
01/2015 - 02/2014
31-dodecylpyridoxal (PLD)IBA
12/2013 - 01/2010
3abagovomabIBA
03/2011 - 12/2008
2AlbuminsIBA
01/2022 - 09/2015
2ChromatinIBA
01/2022 - 01/2021
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 09/2012
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2016 - 01/2016
2lonafarnib (SCH 66336)IBA
11/2015 - 08/2012
2Tyrosine Kinase InhibitorsIBA
12/2013 - 01/2005
2EnzymesIBA
12/2013 - 07/2010
2Cytochrome P-450 CYP2C8IBA
05/2013 - 07/2011
2Poly Adenosine Diphosphate RiboseIBA
06/2011 - 07/2010
2Progesterone Receptors (Progesterone Receptor)IBA
01/2009 - 06/2007
2Gefitinib (Iressa)FDA Link
04/2007 - 01/2005
2Indicators and Reagents (Reagents)IBA
10/2006 - 01/2005
1Aromatase InhibitorsIBA
05/2022
1Letrozole (Femara)FDA LinkGeneric
05/2022
1Immune Checkpoint InhibitorsIBA
02/2022
1Circulating Tumor DNAIBA
01/2022
1Factor XIII (Coagulation Factor XIII)IBA
01/2022
1Cell-Free Nucleic AcidsIBA
12/2021

Therapy/Procedure

55Drug Therapy (Chemotherapy)
04/2022 - 09/2003
47Therapeutics
05/2022 - 04/2005
18Cytoreduction Surgical Procedures
01/2022 - 09/2005
16Neoadjuvant Therapy
04/2022 - 11/2006
11Lymph Node Excision (Lymph Node Dissection)
01/2021 - 04/2010
4Adjuvant Chemotherapy
07/2013 - 05/2009
3Hyperthermic Intraperitoneal Chemotherapy
11/2018 - 01/2017
3Combination Drug Therapy (Combination Chemotherapy)
11/2016 - 05/2007
2Radiotherapy
10/2019 - 03/2015
1Art Therapy
01/2020
1Conservative Treatment
01/2020